CN102438648A - 用于治疗胰腺β细胞功能障碍的组织激肽释放酶 - Google Patents

用于治疗胰腺β细胞功能障碍的组织激肽释放酶 Download PDF

Info

Publication number
CN102438648A
CN102438648A CN2010800181825A CN201080018182A CN102438648A CN 102438648 A CN102438648 A CN 102438648A CN 2010800181825 A CN2010800181825 A CN 2010800181825A CN 201080018182 A CN201080018182 A CN 201080018182A CN 102438648 A CN102438648 A CN 102438648A
Authority
CN
China
Prior art keywords
purified
seq
klk1
isolated
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800181825A
Other languages
English (en)
Chinese (zh)
Inventor
M·威廉姆斯
K·理查德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diamedica Therapeutics Inc
Original Assignee
Diamedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamedica Inc filed Critical Diamedica Inc
Publication of CN102438648A publication Critical patent/CN102438648A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN2010800181825A 2009-03-25 2010-03-25 用于治疗胰腺β细胞功能障碍的组织激肽释放酶 Pending CN102438648A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16317309P 2009-03-25 2009-03-25
US61/163,173 2009-03-25
PCT/CA2010/000413 WO2010108262A1 (en) 2009-03-25 2010-03-25 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION

Publications (1)

Publication Number Publication Date
CN102438648A true CN102438648A (zh) 2012-05-02

Family

ID=42780097

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800181825A Pending CN102438648A (zh) 2009-03-25 2010-03-25 用于治疗胰腺β细胞功能障碍的组织激肽释放酶

Country Status (8)

Country Link
US (1) US20120070425A1 (enExample)
EP (1) EP2411042A4 (enExample)
JP (1) JP2012521366A (enExample)
CN (1) CN102438648A (enExample)
AU (1) AU2010228068A1 (enExample)
CA (1) CA2756801A1 (enExample)
NZ (1) NZ595364A (enExample)
WO (1) WO2010108262A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
US20140205578A1 (en) * 2011-06-17 2014-07-24 The John Hopkins University Methods for increasing insulin sensitivity and treating diabetes
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
CN104073482A (zh) 2013-12-30 2014-10-01 江苏众红生物工程创药研究院有限公司 聚乙二醇化的组织激肽释放酶及其制备方法和应用
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
CN112481268B (zh) * 2021-01-25 2024-01-30 河南大学 一种棉花启动子PGhPGF及其重组载体和应用
CN116135973A (zh) * 2021-11-16 2023-05-19 江苏众红生物工程创药研究院有限公司 低糖基化修饰的激肽原酶及其聚乙二醇修饰物和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384199A (zh) * 2001-02-20 2002-12-11 深圳市人民医院 一种表达人胰腺组织激肽释放酶基因的重组表达载体及重组人胰腺组织激肽释放酶的制备
CN1521257A (zh) * 2003-01-29 2004-08-18 中国科学院大连化学物理研究所 人组织激肽释放酶的微囊化细胞及其微囊化方法和应用
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
CN101134953A (zh) * 2007-07-02 2008-03-05 广东天普生化医药股份有限公司 重组人胰激肽原酶
CN101255438A (zh) * 2008-04-11 2008-09-03 深圳大学 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
JP2002516261A (ja) * 1998-05-22 2002-06-04 エンターメッド インコーポレイテッド セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
WO2008011713A1 (en) * 2006-07-26 2008-01-31 Diamedica Inc. Methods of diagnosis and treatment for metabolic disorders
EP2051707B1 (en) * 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384199A (zh) * 2001-02-20 2002-12-11 深圳市人民医院 一种表达人胰腺组织激肽释放酶基因的重组表达载体及重组人胰腺组织激肽释放酶的制备
CN1521257A (zh) * 2003-01-29 2004-08-18 中国科学院大连化学物理研究所 人组织激肽释放酶的微囊化细胞及其微囊化方法和应用
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
CN101134953A (zh) * 2007-07-02 2008-03-05 广东天普生化医药股份有限公司 重组人胰激肽原酶
CN101255438A (zh) * 2008-04-11 2008-09-03 深圳大学 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法

Also Published As

Publication number Publication date
CA2756801A1 (en) 2010-09-30
WO2010108262A1 (en) 2010-09-30
NZ595364A (en) 2013-09-27
AU2010228068A1 (en) 2011-10-20
US20120070425A1 (en) 2012-03-22
EP2411042A4 (en) 2012-12-12
JP2012521366A (ja) 2012-09-13
EP2411042A1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
Wynne et al. Diabetes of the exocrine pancreas
Zatorski et al. Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectives
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
WO2010108262A1 (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION
US11938172B2 (en) Method for regulating and controlling GLP-1/GLP-1R and drug
CN101914150B (zh) 一种多肽及其在制药中的应用
Otsuki Pathophysiological role of cholecystokinin in humans
EA013821B1 (ru) Проостровковые пептиды человека, их производные и аналоги и способы их применения
TWI642442B (zh) 纖溶酶原在製備降低胰高血糖素分泌的藥物上的用途
Emerich et al. The testicular-derived Sertoli cell: cellular immunoscience to enable transplantation
Boj-Carceller Proton pump inhibitors: impact on glucose metabolism
US20010021696A1 (en) Prevention of diabetes
Shaikh et al. Advanced approaches in insulin delivery
US7795385B2 (en) Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
CN108210907A (zh) 治疗糖尿病的新药物及其用途
Whitcomb Molecular and genetic mechanisms of acute and chronic pancreatitis
CN118525087A (zh) 脂肪酶制剂及其方法
Martins-Santos et al. Effect of a pool of peptides isolated from crotalus durissus terrificus (South American Rattlesnake) venom on glucose levels of mice fed on a high-fat diet
Lovshin Glucagon-like peptide-2 (GLP-2) receptor expression in the central nervous system and gastrointestinal tract
JPWO2000062796A1 (ja) 膵臓機能障害改善剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120502

WD01 Invention patent application deemed withdrawn after publication